Personalized Medicine and Mood Disorders

Psychiatric Clinics of North America

Volumn 38, Issue 3, 2015, Pages 395-403

  Alhajji, Lujain ^a   Nemeroff, Charles B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Bipolar disorder; Epigenetics; Major depressive disorder; Personalized medicine; Pharmacogenomics; Precision medicine

Indexed keywords

CYTOCHROME P450 2D6; DRUG METABOLITE;

BIPOLAR DISORDER; CIRCADIAN RHYTHM; DNA MODIFICATION; ENZYME ACTIVITY; ENZYME ASSAY; EPIGENETICS; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MOOD DISORDER; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; TREATMENT RESPONSE; ENDOPHENOTYPE; GENETICS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; MOOD DISORDERS; PATHOPHYSIOLOGY; PHARMACOGENETICS; PROCEDURES;

CIRCADIAN RHYTHM; ENDOPHENOTYPES; EPIGENOMICS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MOOD DISORDERS; PHARMACOGENETICS; PITUITARY-ADRENAL SYSTEM; PRECISION MEDICINE;

EID: 84941166959     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2015.05.003     Document Type: Review

References (32)

1. Kessler R.C., McGonagle K.A., Zhao S., et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994, 51:8-19.
2. Pratt L.A., Brody D.J., Gu Q. Antidepressant use in persons aged 12 and over: United States, 2005-2006. NCHS data brief, no 76 2011, National Center for Health Statistics, Hyattsville (MD).
3. Trivedi M.H., Rush A.J., Wisniewski S.R., STAR*D Study Team, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.
4. Smoller J.W., Finn C.T. Family, twin, and adoption studies of bipolar disorder. Am J Med Genet C Semin Med Genet 2003, 123C(1):48-58.
5. Thakur M., Grossman I., McCroy D.C., et al. Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. Genet Med 2007, 9:826-835.
6. Hoefgen B., Schulze T.G., Ohlraun S., et al. The power of sample size and homogenous sampling: association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder. Biol Psychiatry 2005, 57(3):247-251.
7. Caspi A., Sugdon K., Moffitt T.E., et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
8. Gatt J.M., Williams L.M., Schofield P.R., et al. Impact of the HTR3A gene with early life trauma on emotional brain networks and depressed mood. Depress Anxiety 2010, 27(8):752-759.
9. Gatt J.M., Nemeroff C.B., Schofield P.R., et al. Early life stress combined with serotonin 3A receptor and brain-derived neurotrophic factor valine 66 to methionine genotypes impacts emotional brain and arousal correlates of risk for depression. Biol Psychiatry 2010, 68(9):818-824.
10. Myers A.J., Nemeroff C.B. New vistas in the management of treatment refractory psychiatric disorders: genomics and personalized medicine. Focus 2010, 8:525-535.
11. Binder E., Salyakina D., Lichtner P., et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004, 36:1319-1325.
12. Brent D., Melhem N., Ferrell R., et al. Association of FKBP5 polymorphisms with suicidal events in the treatment of resistant depression in adolescents (TORDIA) study. Am J Psychiatry 2010, 167(2):190-197.
13. Klengal T., Mehta D., Anacker C., et al. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci 2013, 16:33-41.
14. Liu Z., Zhu F., Wang G., et al. Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression. Neurosci Lett 2006, 404(3):358-362.
15. Bradley R., Binder E., Epstein M.P., et al. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry 2008, 65(2):190-200.
16. Claes S., Villafuerte S., Forsgen T., et al. The corticotropin-releasing hormone binding protein is associated with major depression in a population from Northern Sweden. Biol Psychiatry 2003, 54:867-872.
17. Van Den Eede F., Venken T., Del-Favero J., et al. Single nucleotide polymorphism analysis of corticotropin-releasing factor-binding protein gene in recurrent major depressive disorder. Psychiatry Res 2007, 153(1):17-25.
18. Binder E.B., Owens M.J., Liu W., et al. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry 2010, 67(4):369-379.
19. Ellenbogen M.A., Hodgins S., Walker C.D., et al. Daytime cortisol and stress reactivity in the offspring of parent with bipolar disorder. Psychoneuroendocrinology 2006, 31(10):1164-1180.
20. Willour V.L., Chen H., Toolan J., et al. Family-based association of FKBP5 in bipolar disorder. Mol Psychiatry 2009, 14:261-268.
21. Mansour H.A., Wood J., Logue T., et al. Association study of eight circadian genes with bipolar I disorder, schizoaffective disorder and schizophrenia. Genes Brain Behav 2006, 5(2):150-157.
22. Shi J., Wittke-Thompson J.K., Badner J.A., et al. Clock genes may influence bipolar disorder susceptibility and dysfunctional circadian rhythm. Am J Med Genet B Neuropsychiatr Genet 2008, 147B(7):1047-1055.
23. Benedetti F., Dallaspezia S., Fulgosi M.C., et al. Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. Am J Med Genet B Neuropsychiatr Genet 2007, 144B(5):631-635.
24. Tsankova N.M., Berton O., Renthal W., et al. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006, 9:519-525.
25. McGowan P.O., Sasaki A., D'Alessio A.C., et al. Epigenetic regulation of the glucocorticoid receptor in human brain associated with childhood abuse. Nat Neurosci 2009, 12(3):342-348.
26. Lin P.Y. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorders: a meta-analytic study. Neurosci Lett 2009, 466:139-143.
27. Fernandes B.S., Gama C.S., Ceresér K.M., et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011, 45:995-1004.
28. Fernandes B.S., Gama C.S., Kauer-Sant'Anna M., et al. Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. J Psychiatr Res 2009, 43:1200-1204.
29. McGrath C.L., Kelley M.E., Holtzheimer P.E., et al. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry 2013, 70(8):821-829.
30. Dichter G.S., Gibbs D., Smoski M.J. A systematic review of relations between resting-state functional-MRI and treatment response in major depressive disorder. J Affect Disord 2014, 172C:8-17.
31. Phillips M.L., Chase H.W., Sheline Y.I., et al. Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches. Am J Psychiatry 2015, 172:124-138.
32. Etkin A., Patenaude B., Song Y.J., et al. A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. Neuropsychopharmacology 2015, 40(6):1332-1342.